In the primary adjusted model (including age, BMI, diabetes severity, and tumor stage), GLP-1 targeting agent use was associated with significantly reduced odds of achieving pCR (OR 0.22, 95% CI 0.06–0.79), equivalent to a 78% relative reduction in response likelihood. The gene discussed is GLP1R; the disease is diabetes mellitus.